Contact this trialFirst, we need to learn more about you.
Anti-metabolites
CPX-351 + Enasidenib for Acute Myeloid Leukemia
Recruiting3 awardsPhase 2
San Francisco, California
This trial evaluates how two drugs, CPX-351 and enasidenib, work together to treat a type of leukemia. Together, they may be more effective than using just one.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service